A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
Completed
- Conditions
- Infection
- Registration Number
- NCT00724919
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres
- Detailed Description
This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 256
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of surveillance phase 48hours
- Secondary Outcome Measures
Name Time Method The infection rate due to ESBL producing E. coli, or due to K. pneumoniae at the end of surveillance phase 48hours